Prothena (NASDAQ:PRTA) Releases Quarterly Earnings Results, Misses Estimates By $0.06 EPS

Prothena (NASDAQ:PRTA) released its quarterly earnings data on Thursday. The biotechnology company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.06), Zacks reports. Prothena had a negative return on equity of 24.19% and a negative net margin of 98.86%.

Prothena Trading Up 1.8 %

Prothena stock traded up $0.27 during trading hours on Thursday, hitting $15.25. 357,579 shares of the stock traded hands, compared to its average volume of 366,469. The firm’s 50-day moving average price is $14.25 and its two-hundred day moving average price is $16.84. The company has a market cap of $820.60 million, a PE ratio of -6.15 and a beta of 0.08. Prothena has a one year low of $11.70 and a one year high of $31.03.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $48.00 price objective (down previously from $84.00) on shares of Prothena in a report on Friday, December 20th. Chardan Capital initiated coverage on Prothena in a research note on Friday, December 20th. They issued a “buy” rating and a $40.00 target price on the stock. Bank of America cut their target price on Prothena from $26.00 to $22.00 and set a “neutral” rating on the stock in a research note on Thursday, December 19th. Oppenheimer raised their target price on Prothena from $58.00 to $62.00 and gave the stock an “outperform” rating in a research note on Friday, February 7th. Finally, StockNews.com cut Prothena from a “hold” rating to a “sell” rating in a research note on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $46.50.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.